Sukeyuki Nakamura
Overview
Explore the profile of Sukeyuki Nakamura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
99
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hirano S, Takahashi H, Nakamura S, Matsuda K, Ishikawa R, Tamura K, et al.
Chin Clin Oncol
. 2024 Jun;
13(3):43.
PMID: 38859608
Background: Immune checkpoint inhibitors (ICIs) have become key agents in the treatment of non-small cell lung cancer worldwide. However, immune-related adverse events (irAEs) must be addressed to maximize the efficacy...
2.
Aoki A, Iwamura C, Kiuchi M, Tsuji K, Sasaki A, Hishiya T, et al.
J Clin Immunol
. 2024 Apr;
44(4):104.
PMID: 38647550
Purpose: Auto-antibodies (auto-abs) to type I interferons (IFNs) have been identified in patients with life-threatening coronavirus disease 2019 (COVID-19), suggesting that the presence of auto-abs may be a risk factor...
3.
Fujita T, Amano H, Nakamura M, Hirano S, Nakamura S
J Thorac Oncol
. 2023 Aug;
18(9):e93-e94.
PMID: 37599053
No abstract available.
4.
Fujita T, Amano H, Nakamura M, Ishikawa R, Inazaki T, Urano Y, et al.
Respir Investig
. 2023 Jun;
61(4):508-510.
PMID: 37267851
No abstract available.
5.
Kawamura K, Matsushima H, Sakai H, Iwashima A, Nakamura S, Kojima T, et al.
Oncology
. 2022 Sep;
100(11):620-632.
PMID: 36099876
Introduction: Cisplatin-based chemotherapy was established in the 1980s, and it has been improved by the development of a short hydration protocol in lung cancer therapy. However, cisplatin-based chemotherapy is still...
6.
Iwamura C, Hirahara K, Kiuchi M, Ikehara S, Azuma K, Shimada T, et al.
Proc Natl Acad Sci U S A
. 2022 Jul;
119(33):e2203437119.
PMID: 35895716
The mortality of coronavirus disease 2019 (COVID-19) is strongly correlated with pulmonary vascular pathology accompanied by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-triggered immune dysregulation and aberrant activation of...
7.
Fujita T, Kuroki T, Hayama N, Shiraishi Y, Amano H, Nakamura M, et al.
Intern Med
. 2020 May;
59(16):1939-1945.
PMID: 32389949
Objective Pembrolizumab has benefited patients with advanced non-small-cell lung cancer (NSCLC) with a programmed death-ligand (PD-L) 1 high expression, but little information is available regarding its safety for patients with...
8.
Hirano S, Hayama N, Tabeta H, Kuroki T, Shiraishi Y, Fujita T, et al.
J Thorac Oncol
. 2019 Dec;
15(1):e20-e22.
PMID: 31864556
No abstract available.
9.
Fujita T, Kuroki T, Hayama N, Shiraishi Y, Amano H, Nakamura M, et al.
In Vivo
. 2019 Oct;
33(6):2059-2064.
PMID: 31662538
Background/aim: Pemetrexed plus platinum followed by pemetrexed maintenance has been one of the standard first-line treatments in advanced nonsquamous non-small cell lung cancer (NSCLC), but little is known regarding its...
10.
Fujita T, Hayama N, Kuroki T, Shiraishi Y, Amano H, Nakamura M, et al.
Thorac Cancer
. 2019 Sep;
10(11):2179-2182.
PMID: 31512401
The safety of treatment with immune-checkpoint inhibitors prior to thoracic surgery in patients with non-small cell lung cancer (NSCLC) remains unclear. Here, we describe the case of a 62-year-old woman...